These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 29516413)

  • 1. Interplay between adenosine receptor antagonist and cyclooxygenase inhibitor in haloperidol-induced extrapyramidal effects in mice.
    Arora D; Mudgal J; Nampoothiri M; Mallik SB; Kinra M; Hall S; Anoopkumar-Dukie S; Grant GD; Rao CM
    Metab Brain Dis; 2018 Aug; 33(4):1045-1051. PubMed ID: 29516413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
    Tada M; Shirakawa K; Matsuoka N; Mutoh S
    Psychopharmacology (Berl); 2004 Oct; 176(1):94-100. PubMed ID: 15083255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of cyclooxygenase inhibitors on haloperidol-induced catalepsy.
    Naidu PS; Kulkarni SK
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Jun; 26(5):819-22. PubMed ID: 12369252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of adenosine A2A receptor antagonists on haloperidol-induced movement disorders in primates.
    Varty GB; Hodgson RA; Pond AJ; Grzelak ME; Parker EM; Hunter JC
    Psychopharmacology (Berl); 2008 Oct; 200(3):393-401. PubMed ID: 18594798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP.
    Shiozaki S; Ichikawa S; Nakamura J; Kitamura S; Yamada K; Kuwana Y
    Psychopharmacology (Berl); 1999 Nov; 147(1):90-5. PubMed ID: 10591873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of antipsychotic-induced extrapyramidal side effects by medications for mood disorders.
    Tatara A; Shimizu S; Shin N; Sato M; Sugiuchi T; Imaki J; Ohno Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Aug; 38(2):252-9. PubMed ID: 22542492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behavioural effects of chronic haloperidol and risperidone treatment in rats.
    Karl T; Duffy L; O'brien E; Matsumoto I; Dedova I
    Behav Brain Res; 2006 Aug; 171(2):286-94. PubMed ID: 16697060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The orexin-1 antagonist SB-334867 blocks antipsychotic treatment emergent catalepsy: implications for the treatment of extrapyramidal symptoms.
    Rasmussen K; Hsu MA; Noone S; Johnson BG; Thompson LK; Hemrick-Luecke SK
    Schizophr Bull; 2007 Nov; 33(6):1291-7. PubMed ID: 17660489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antagonism of haloperidol-induced swim impairment in L-dopa and caffeine treated mice: a pre-clinical model to study Parkinson's disease.
    Luthra PM; Barodia SK; Raghubir R
    J Neurosci Methods; 2009 Apr; 178(2):284-90. PubMed ID: 19146880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of presynaptic 5-HT
    Mombereau C; Arnt J; Mørk A
    Pharmacol Biochem Behav; 2017 Feb; 153():141-146. PubMed ID: 28057524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antipsychotic-induced catalepsy is attenuated in mice lacking the M4 muscarinic acetylcholine receptor.
    Fink-Jensen A; Schmidt LS; Dencker D; Schülein C; Wess J; Wörtwein G; Woldbye DP
    Eur J Pharmacol; 2011 Apr; 656(1-3):39-44. PubMed ID: 21269601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of adjunct galantamine to risperidone, or haloperidol, in animal models of antipsychotic activity and extrapyramidal side-effect liability: involvement of the cholinergic muscarinic receptor.
    Wadenberg ML; Fjällström AK; Federley M; Persson P; Stenqvist P
    Int J Neuropsychopharmacol; 2011 Jun; 14(5):644-54. PubMed ID: 20701827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of NR-ANX-C (a polyherbal formulation) on haloperidol induced catalepsy in albino mice.
    Nair V; Arjuman A; Dorababu P; Gopalakrishna HN; Chakradhar Rao U; Mohan L
    Indian J Med Res; 2007 Nov; 126(5):480-4. PubMed ID: 18160755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preladenant, a selective A(2A) receptor antagonist, is active in primate models of movement disorders.
    Hodgson RA; Bedard PJ; Varty GB; Kazdoba TM; Di Paolo T; Grzelak ME; Pond AJ; Hadjtahar A; Belanger N; Gregoire L; Dare A; Neustadt BR; Stamford AW; Hunter JC
    Exp Neurol; 2010 Oct; 225(2):384-90. PubMed ID: 20655910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tea component, epigallocatechin gallate, potentiates anticataleptic and locomotor-sensitizing effects of caffeine in mice.
    Kasture SB; Gaikar M; Kasture V; Arote S; Salve B; Rosas M; Cotti E; Acquas E
    Behav Pharmacol; 2015 Feb; 26(1-2):125-32. PubMed ID: 25144514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergism of theophylline and anticholinergics to inhibit haloperidol-induced catalepsy: a potential treatment for extrapyramidal syndromes.
    González-Lugo OE; Ceballos-Huerta F; Jiménez-Capdeville ME; Arankowsky-Sandoval G; Góngora-Alfaro JL
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Dec; 34(8):1465-71. PubMed ID: 20713114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors in mice.
    Sonego AB; Gomes FV; Del Bel EA; Guimaraes FS
    Behav Brain Res; 2016 Aug; 309():22-8. PubMed ID: 27131780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potency and efficacy of anticholinergics to inhibit haloperidol-induced catalepsy in rats correlates with their rank order of affinities for the muscarinic receptor subtypes.
    Erosa-Rivero HB; Bata-García JL; Alvarez-Cervera FJ; Heredia-López FJ; Góngora-Alfaro JL
    Neuropharmacology; 2014 Jun; 81():176-87. PubMed ID: 24534110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential antipsychotic and extrapyramidal effects of (R,S)-3,4-dicarboxyphenylglycine [(R,S)-3,4-DCPG], a mixed AMPA antagonist/mGluR8 agonist.
    Ossowska K; Pietraszek M; Wardas J; Wolfarth S
    Pol J Pharmacol; 2004; 56(3):295-304. PubMed ID: 15215559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction between anti-Alzheimer and antipsychotic drugs in modulating extrapyramidal motor disorders in mice.
    Shimizu S; Mizuguchi Y; Sobue A; Fujiwara M; Morimoto T; Ohno Y
    J Pharmacol Sci; 2015 Apr; 127(4):439-45. PubMed ID: 25850380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.